The mechanism may lie in the significant elevation of the expression of RhoA, ROCK, vinculin, and the ratio of p-FAK/FAK by regulating the RhoA/ROCK signaling pathway, thereby providing experimental evidence and modifying the target of LIPUS in osteoradionecrosis treatment practice. The gene discussed is PTK2; the disease is osteoradionecrosis.